Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005

Urology

Volumn 69, Issue 6, 2007, Pages 1095-1101

  Makarov, Danil V ^a   Trock, Bruce J ^a   Humphreys, Elizabeth B ^a   Mangold, Leslie A ^a   Walsh, Patrick C ^a   Epstein, Jonathan I ^a   Partin, Alan W ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER REGISTRY; CANCER STAGING; CLINICAL EVALUATION; COHORT ANALYSIS; GLEASON SCORE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NOMOGRAM; PARTIN TABLE; PATIENT DECISION MAKING; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SEMINAL VESICLE;

ADULT; AGED; BIOPSY, NEEDLE; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34250012314     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.03.042     Document Type: Article

References (30)

1. Blute M.L., Nativ O., Zincke H., et al. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 142 (1989) 1262-1265
2. Epstein J.I., Pizov G., and Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71 (1993) 3582-3593
3. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
4. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
5. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
6. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
7. Aleman M., Karakiewicz P.I., Kupelian P., et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 62 (2003) 70-74
8. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 (2003) 1798-1803
9. Kattan M.W., Eastham J.A., Wheeler T.M., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
10. Kattan M.W., Stapleton A.M., Wheeler T.M., et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79 (1997) 528-537
11. Ohori M., Kattan M.W., Koh H., et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 171 (2004) 1844-1849
12. Wang L., Hricak H., Kattan M.W., et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238 (2006) 597-603
13. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
14. Han M., Partin A.W., Chan D.Y., et al. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 171 (2004) 23-26
15. Blute M.L., Bergstralh E.J., Partin A.W., et al. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol 164 (2000) 1591-1595
16. Karakiewicz P.I., Lattouf J.B., Perrotte P., et al. Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec. Can J Urol 12 (2005) 2588-2592
17. Eskicorapci S.Y., Karabulut E., Turkeri L., et al. Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol 47 (2005) 185-189
18. Penson D.F., Grossfeld G.D., Li Y.P., et al. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population?. Results of the cancer of the prostate strategic urological research endeavor. J Urol 167 (2002) 1653-1658
19. Epstein J.I. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 24 (2000) 477-478
20. Han M., Partin A.W., Pound C.R., et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 28 (2001) 555-565
21. Han M., Snow P.B., Epstein J.I., et al. A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. Urology 56 (2000) 994-999
22. Makarov D.V., Sanderson H., Partin A.W., et al. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. J Urol 167 (2002) 2440-2442
23. Harrell Jr. F.E., Califf R.M., Pryor D.B., et al. Evaluating the yield of medical tests. JAMA 247 (1982) 2543-2546
24. Makarov D.V., Humphreys E.B., Mangold L.A., et al. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. J Urol 176 (2006) 554-558
25. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97 (2005) 1248-1253
26. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
27. Punglia R.S., D'Amico A.V., Catalona W.J., et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349 (2003) 335-342
28. Catalona W.J., Smith D.S., and Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 (1997) 1452-1455
29. Jang T.L., Han M., Roehl K.A., et al. More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects. Urology 67 (2006) 343-348
30. Feinstein A.R., Sosin D.M., and Wells C.K. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312 (1985) 1604-1608